Secondary Prevention of ASCVD
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Secondary Prevention of ASCVD
-
ナレーター：
-
著者：
A 55-year-old man is seen in follow up six weeks post hospitalization for acute coronary syndrome with drug eluding stent placement, has a 40-pack-year cigarette smoking history and currently smokes two packs of cigarettes per day. His medical history is also significant for stage 3-A CKD, with current estimated GFR of 52. His medications include high-intensity statin therapy and ezetimibe or Zetia, along with standard post ACS and CKD therapies. He states he's feeling well and taking all his medications as advised without adverse effects. Laboratory results today reveal an LDL cholesterol of 98, HDL of 35, triglycerides of 154.
Which of the following is the most appropriate next step in lipid management?
A. As he is feeling well, an LDL cholesterol is post ACS goal. Continue current therapy.
B. Due to his GFR, discontinue Zetia and substitute with bempedoic acid.
C. Add a PCSK9 inhibitor to current regimen.
D. Advise that moderate intensity statin therapy is preferred in stage 3-A CKD.
Visit fhea.com to learn more!